A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT07330778
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mild to Moderate Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Celldex Therapeutics
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Francisco · San Francisco, CA
Kansas · 1
- The University of Kansas Medical Center · Kansas City, KS
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
Pennsylvania · 1
- University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.